GENGYVE® Precision Rinse: Biofunctional Innovation for Dental Excellence
Transform your practice with clinically-proven oral care that delivers efficacy, safety, and scalability. Where hygiene becomes a revenue engine without compromising patient outcomes.
Learn More
Turning Hygiene Into Growth
Hygiene isn't just a cost center — it's a revenue engine. With GENGYVE® Precision Rinse, your practice can generate significant additional revenue while improving patient outcomes.
Our solution delivers $18,000+ per site annually, scaling to $360,000 at 20 locations and over $1 million at 50 sites. With margins of $9 per bottle and volume pricing options, you're looking at substantial profit increases.

Financial Impact at a Glance
  • $18,000+ revenue per site annually
  • $360,000 potential at 20 sites
  • Over $1 million at 50 sites
  • $9 margin per bottle, higher with volume
  • OTC + FSA/HSA eligibility drives patient uptake
With OTC accessibility and FSA/HSA eligibility, GENGYVE® broadens patient access and drives adoption. It's low lift, high yield — incremental profit built right into your routine care protocols.
Clinical Integrity Without Compromise
Problem with CHX
The science has always pointed to Chlorhexidine (CHX), but staining and adverse events limit long-term use.
GENGYVE® Solution
CPC+HA formulation delivers CHX-equivalent plaque control with superior tolerability and no staining.
Clinical Results
RCT evidence shows 20% adverse events with CPC+HA versus 40% with CHX, while maintaining equivalent efficacy.
The mechanism is clear: CPC effectively reduces microbial load while HA accelerates wound healing. The result is comparable efficacy with superior tolerability, specifically designed for the long-term use that drives practice revenue and patient health.
Research Validation: Evidence by Active
Cetylpyridinium Chloride (CPC)
Multiple randomized controlled trials and systematic reviews demonstrate significant plaque and gingivitis reduction comparable to CHX. Clinical data shows plaque index changes with CPC+HA overlapping CHX efficacy, both far superior to placebo.
Hyaluronic Acid (HA)
Delivers anti-inflammatory, bacteriostatic, and barrier-forming properties that improve gingival indices and accelerate wound healing. Studies confirm gingival index improvements when HA is used as an adjunct, significantly reducing inflammation post-SRP.
Castor Oil (Ricinoleic Acid)
Exhibits proven antimicrobial, anti-inflammatory, and hydrating properties in both in vitro and topical application models, enhancing overall formula performance and patient comfort.
Film-Forming Technology
  • Pullulan: Natural polysaccharide that forms a protective film, enhancing retention and delivery of actives with 40% biofilm inhibition compared to controls
  • Polyvinylpyrrolidone (PVP): Safe, inert film-former that increases substantivity, nearly doubling the residence time of actives in the oral cavity
Takeaway: This synergistic formulation controls plaque maturation, supports tissue repair, and ensures sustained substantivity. Clinical proof + mechanistic rationale = validated innovation.
Seamless Integration Into Your Practice
Adoption Should Feel Natural, Not Forced
GENGYVE® Precision Rinse integrates effortlessly into your existing workflows. Hygienists recommend it chairside, while surgeons include it as a standard component in post-operative care kits.
Our comprehensive support includes protocol cards, QR-code education materials, and reorder-ready cases that streamline implementation from clinic to patient.
01
Hygienist Recommendation
Introduce during routine appointments
02
Surgical Integration
Include in all post-op kits
03
Patient Education
Utilize QR-codes and protocol cards
04
Reordering
Streamlined bulk purchasing with discounts
With bulk discounts and predictable supply chains, we've removed all friction from the adoption process. From clinic to patient, it's truly plug-and-play implementation.
Elevating the Patient Experience
When patients embrace a product, compliance follows naturally. GENGYVE® Precision Rinse delivers a superior experience that patients actually want to use:
Comfort
Stain-free formula with pleasant flavor profile encourages regular use
Healing
HA barrier formation and anti-inflammatory effects support comfort and accelerate healing
Affordability
FSA/HSA eligibility makes premium care accessible without premium pricing
The patient conversation is straightforward: "This is a professional-grade rinse that both heals and protects, and your FSA covers it."
The result? Confidence at the chair, satisfaction at home.
A Story That Resonates
Science persuades professionals, but story engages patients. GENGYVE® delivers both with a compelling narrative:
  • Developed by an oral surgeon with real-world clinical experience
  • Veteran-owned company committed to excellence
  • Biofunctional approach that addresses both symptoms and causes
The systemic health hook connects oral inflammation to serious conditions like cardiovascular disease, diabetes, and Alzheimer's—giving patients a reason to care beyond just clean teeth.

Our Competitive Edge
GENGYVE® is the only rinse on the market blending:
  • CHX-level efficacy
  • OTC accessibility
  • Tissue-healing capacity
This unique combination creates credibility that commands trust and branding that drives adoption.
Our storytelling provides your team with powerful talking points that connect oral health to whole-body wellness—making the value proposition clear to patients from all walks of life.
Beyond the Mouth: The Systemic Connection
Oral biofilm isn't merely a local concern—it fuels systemic inflammation throughout the body. The mechanism is clear: dysbiosis in the oral cavity leads to increased inflammatory markers including IL-6, TNF-α, and CRP.
Oral Dysbiosis
Plaque biofilm creates local inflammation and bacterial byproducts
Systemic Spread
Inflammatory markers enter circulation, affecting distant organs
Disease Progression
Links to heart disease, diabetes complications, and neurodegeneration
GENGYVE's CPC+HA formula halts plaque maturation without the compliance loss associated with traditional rinses. The result? Control plaque locally, protect the body globally.
Where Others Fall Short
When measured against the field, the gap becomes obvious. GENGYVE® Precision Rinse offers a unique combination of benefits that competing products simply can't match:
Only GENGYVE® delivers the complete package: proven efficacy without staining, enhanced healing support with dual-weight hyaluronic acid, high patient compliance, and FSA/HSA eligibility to drive accessibility and adoption.
The No-Brainer Decision for Dental Groups
When clinical validation, economic logic, and operational ease converge, the decision becomes remarkably simple. GENGYVE® Precision Rinse delivers across every critical dimension:
Profitable Revenue
Generate $18,000+ per site annually with scalable growth as you expand
Evidence-Based
Backed by peer-reviewed research and randomized controlled trials demonstrating efficacy and safety
Seamless Integration
Plugs directly into existing workflows with minimal training and maximum uptake
Patient Preference
Patients accept and prefer it, driving compliance and treatment outcomes
Next Step:
Pilot GENGYVE® Precision Rinse across your hygiene and surgical departments with advantageous 10+ case pricing. Watch as patient satisfaction, clinical outcomes, and your bottom line all improve simultaneously.
Control Plaque. Heal Tissue. Protect the Body — and Your Bottom Line.
GENGYVE® Precision Rinse represents the convergence of clinical excellence and business opportunity. Our biofunctional innovation delivers the efficacy dental professionals demand with the safety patients deserve.
With our differentiated, story-rich brand equity, you'll not only improve clinical outcomes but also create a significant new revenue stream that scales with your practice.
Join the leading dental groups already transforming hygiene from a cost center to a profit center with GENGYVE®.

"GENGYVE has become an essential part of our practice. Patients love it, clinicians trust it, and our CFO is thrilled with the revenue impact."
— Leading Dental Group CEO